The long-term effect of alprenolol on plasma apolipoproteins A-I and B.
Acta Med Scand
; 223(5): 419-22, 1988.
Article
en En
| MEDLINE
| ID: mdl-3132028
The concentration of lipids, lipoproteins and apolipoprotein A-I and B was measured in the plasma of 33 patients, enrolled in a double-blind, controlled trial of alprenolol in myocardial infarction, after one year on the study medication and again after 6 months off the medication. Sixteen patients received 200 mg alprenolol twice daily and 17 received placebo. There were no statistically significant differences between the parameters in the two groups after one year on medication. However, when medication was stopped, the ratio of apolipoprotein B to apolipoprotein A-I fell by 9% in the alprenolol group and increased by 2% in the placebo group. This difference was statistically significant. Our results suggest that alprenolol, a beta-blocker with weak intrinsic sympathomimetic effect, has slight effects on plasma lipoproteins. These effects were apparent only by measurements of apolipoproteins.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Apolipoproteínas A
/
Apolipoproteínas B
/
Alprenolol
/
Infarto del Miocardio
Tipo de estudio:
Clinical_trials
/
Prognostic_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Acta Med Scand
Año:
1988
Tipo del documento:
Article
Pais de publicación:
Suecia